Cargando…

Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus

BACKGROUND: Cardiovascular disease (CVD) is frequent in type 2 diabetes mellitus patients due to accelerated atherosclerosis. Plasma osteoprotegerin (OPG) has evolved as a biomarker for CVD. We examined the relationship between plasma OPG levels and different CVD manifestations in type 2 diabetes. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulsen, Mikael K, Nybo, Mads, Dahl, Jordi, Hosbond, Susanne, Poulsen, Tina S, Johansen, Allan, Høilund-Carlsen, Poul F, Beck-Nielsen, Henning, Rasmussen, Lars M, Henriksen, Jan E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163516/
https://www.ncbi.nlm.nih.gov/pubmed/21838881
http://dx.doi.org/10.1186/1475-2840-10-76
_version_ 1782210951837122560
author Poulsen, Mikael K
Nybo, Mads
Dahl, Jordi
Hosbond, Susanne
Poulsen, Tina S
Johansen, Allan
Høilund-Carlsen, Poul F
Beck-Nielsen, Henning
Rasmussen, Lars M
Henriksen, Jan E
author_facet Poulsen, Mikael K
Nybo, Mads
Dahl, Jordi
Hosbond, Susanne
Poulsen, Tina S
Johansen, Allan
Høilund-Carlsen, Poul F
Beck-Nielsen, Henning
Rasmussen, Lars M
Henriksen, Jan E
author_sort Poulsen, Mikael K
collection PubMed
description BACKGROUND: Cardiovascular disease (CVD) is frequent in type 2 diabetes mellitus patients due to accelerated atherosclerosis. Plasma osteoprotegerin (OPG) has evolved as a biomarker for CVD. We examined the relationship between plasma OPG levels and different CVD manifestations in type 2 diabetes. METHODS: Type 2 diabetes patients without known CVD referred consecutively to a diabetes clinic for the first time (n = 305, aged: 58.6 ± 11.3 years, diabetes duration: 4.5 ± 5.3 years) were screened for carotid arterial disease, peripheral arterial disease, and myocardial ischemia by means of carotid artery ultrasonography, peripheral ankle and toe systolic blood pressure measurements, and myocardial perfusion scintigraphy (MPS). In addition, plasma OPG concentrations and other CVD-related markers were measured. RESULTS: The prevalence of carotid arterial disease, peripheral arterial disease, and myocardial ischemia was 42%, 15%, and 30%, respectively. Plasma OPG was significantly increased in patients with carotid and peripheral arterial disease compared to patients without (p < 0.001, respectively), however, this was not the case for patients with myocardial ischemia versus those without (p = 0.71). When adjusted for age, HbA1c and U-albumin creatinine ratio in a multivariate logistic regression analysis, plasma OPG remained strongly associated with carotid arterial disease (adjusted OR: 2.12; 95% CI: 1.22-3.67; p = 0.008), but not with peripheral arterial disease or myocardial ischemia. CONCLUSIONS: Increased plasma OPG concentration is associated with carotid and peripheral arterial disease in patients with type 2 diabetes, whereas no relation is observed with respect to myocardial ischemia on MPS. The reason for this discrepancy is unknown. TRIAL REGISTRATION NUMBER: at http://www.clinicaltrial.gov: NCT00298844
format Online
Article
Text
id pubmed-3163516
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31635162011-08-30 Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus Poulsen, Mikael K Nybo, Mads Dahl, Jordi Hosbond, Susanne Poulsen, Tina S Johansen, Allan Høilund-Carlsen, Poul F Beck-Nielsen, Henning Rasmussen, Lars M Henriksen, Jan E Cardiovasc Diabetol Original Investigation BACKGROUND: Cardiovascular disease (CVD) is frequent in type 2 diabetes mellitus patients due to accelerated atherosclerosis. Plasma osteoprotegerin (OPG) has evolved as a biomarker for CVD. We examined the relationship between plasma OPG levels and different CVD manifestations in type 2 diabetes. METHODS: Type 2 diabetes patients without known CVD referred consecutively to a diabetes clinic for the first time (n = 305, aged: 58.6 ± 11.3 years, diabetes duration: 4.5 ± 5.3 years) were screened for carotid arterial disease, peripheral arterial disease, and myocardial ischemia by means of carotid artery ultrasonography, peripheral ankle and toe systolic blood pressure measurements, and myocardial perfusion scintigraphy (MPS). In addition, plasma OPG concentrations and other CVD-related markers were measured. RESULTS: The prevalence of carotid arterial disease, peripheral arterial disease, and myocardial ischemia was 42%, 15%, and 30%, respectively. Plasma OPG was significantly increased in patients with carotid and peripheral arterial disease compared to patients without (p < 0.001, respectively), however, this was not the case for patients with myocardial ischemia versus those without (p = 0.71). When adjusted for age, HbA1c and U-albumin creatinine ratio in a multivariate logistic regression analysis, plasma OPG remained strongly associated with carotid arterial disease (adjusted OR: 2.12; 95% CI: 1.22-3.67; p = 0.008), but not with peripheral arterial disease or myocardial ischemia. CONCLUSIONS: Increased plasma OPG concentration is associated with carotid and peripheral arterial disease in patients with type 2 diabetes, whereas no relation is observed with respect to myocardial ischemia on MPS. The reason for this discrepancy is unknown. TRIAL REGISTRATION NUMBER: at http://www.clinicaltrial.gov: NCT00298844 BioMed Central 2011-08-12 /pmc/articles/PMC3163516/ /pubmed/21838881 http://dx.doi.org/10.1186/1475-2840-10-76 Text en Copyright ©2011 Poulsen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Poulsen, Mikael K
Nybo, Mads
Dahl, Jordi
Hosbond, Susanne
Poulsen, Tina S
Johansen, Allan
Høilund-Carlsen, Poul F
Beck-Nielsen, Henning
Rasmussen, Lars M
Henriksen, Jan E
Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
title Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
title_full Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
title_fullStr Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
title_full_unstemmed Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
title_short Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
title_sort plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163516/
https://www.ncbi.nlm.nih.gov/pubmed/21838881
http://dx.doi.org/10.1186/1475-2840-10-76
work_keys_str_mv AT poulsenmikaelk plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT nybomads plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT dahljordi plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT hosbondsusanne plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT poulsentinas plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT johansenallan plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT høilundcarlsenpoulf plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT becknielsenhenning plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT rasmussenlarsm plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus
AT henriksenjane plasmaosteoprotegerinisrelatedtocarotidandperipheralarterialdiseasebutnottomyocardialischemiaintype2diabetesmellitus